Latest news with #Pharmarack
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Lilly's obesity drug Mounjaro's sales rise 60% in India amid rising demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60 per cent in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about ₹7.5 crore, while revenue from the 2.5 mg shot was ₹5.1 crore. 'The patient number may have actually doubled' in May from April, Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is gradually rising and should continue, she said. Newer patients are being introduced with the lower dose and upgraded to 5 mg injections after four weeks, according to Sapale. The increase in sales reflects the need for anti-obesity solutions in the vast market in India, where Danish rival Novo Nordisk A/S is also expected to launch soon. The country's generic drugmakers are awaiting the expiration of some patents from next year to unleash a flurry of copycat treatments. On Tuesday, Biocon Ltd. received approval for Liraglutide, a generic version of Novo Nordisk's type-2 diabetes and anti-obesity drug Victoza. India has about 100 million people living with diabetes and obesity each, Eli Lilly said earlier this year.
Bloomberg
a day ago
- Business
- Bloomberg
Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand
Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full month of being on offer in the South Asian country, which has the world's third-highest number of obese people. The US drugmaker sold 126 million rupees ($1.5 million) worth of the injections last month, according to market analysis firm Pharmarack Technologies. Sales of its 5 mg version more than doubled to about 75 million rupees, while revenue from the 2.5 mg shot was 51 million rupees.
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Indian pharma market grows 7.2% in May led by chronic therapies
Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches Sanket Koul New Delhi The Indian Pharma Market (IPM) grew 7.2 per cent in May this year with almost all major therapies showing positive growth, according to market research firm Pharmarack. Data suggest that big chronic therapies such as cardiac and anti-infectives, which account for nearly 25 per cent of the overall domestic market, recorded value growth of 11.7 per cent and 7.6 per cent, respectively. On the other hand, several smaller supergroups such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth in May at 12.3 per cent and 11.7 per cent, said Sheetal Sapale, vice-president, commercial, Pharmarack. Data suggest that the overall value growth for the IPM in May was driven by price growth and new introductions. The IPM also reported a minuscule 0.4 per cent unit growth during the month, with the chronic segments such as antidiabetics (6.1 per cent) and cardiac (4.8 per cent) performing better than the overall market figure. Experts believe that the antidiabetic segment saw a 6.1 per cent rise in volume in May due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for the IPM between June 2024 and May 2025 stood at 8.1 per cent, leading to a total turnover of over Rs 2.29 trillion, while volumes in the domestic market grew by 1.1 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.4 per cent, 9.5 per cent and 6.5 per cent, respectively. While the top 20 brands in the IPM registered modest monthly value growth in the domestic market during the month, Sun Pharma and Dr Reddy's posted significant monthly value growth at 11.2 per cent each. They were followed by Torrent Pharma and Ipca Laboratories at 10.8 per cent, and Alkem Laboratories at 10.3 per cent monthly value growth. According to Pharmarack data, GlaxoSmithKline's (GSK) antibiotic medication Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands at the MAT level, with sales worth Rs 819 crore and Rs 810 crore, respectively.
&w=3840&q=100)
Business Standard
07-05-2025
- Business
- Business Standard
India's pharma market grows 7.8% in April, led by chronic therapies
The Indian pharmaceutical market (IPM) grew 7.8 per cent in April this year, with almost all major therapies showing positive value growth, according to market research firm Pharmarack. India Ratings and Research said the continued revenue growth was driven by companies' price hikes, with volume growing 1.3 per cent year-on-year (Y-o-Y). 'India Ratings expects IPM to grow 7-8% Y-o-Y during the financial year 2025-26 (FY26) with sustained growth momentum in the chronic therapies, led by price increases and product launches', said Nishith Sanghvi, director, corporate ratings, India Ratings. Therapies such as cardiac and gastrointestinal, accounting for nearly 25 per cent of the overall domestic market, recorded value growth of 11 per cent and 7.3 per cent, respectively. Several super groups, such as urology and antineoplastics, which made up 2 per cent each of the IPM's sales value for the month, also recorded double-digit growth. Sheetal Sapale, vice-president (commercial) at Pharmarack, said that the price growth and new introductions drove the growth in April, with a negligible volume rise. 'The IPM also reported a positive 1.3 per cent unit growth during the month, with the cardiac and antidiabetic segments performing better than the overall market figure,' she added. Analysis suggests that the antidiabetic segment saw a 4.3 per cent rise in volume sales in April due to a key drug, empagliflozin, going off-patent, as companies launched several plain and combination medications in the segment. Growth in the moving annual turnover (MAT) for IPM between April 2024 and March 2025 stood at 8.3 per cent, leading to a total turnover of over ₹2.27 trillion, while volumes in the domestic market grew by 1.3 per cent. The MAT of leading therapy areas such as cardiac, gastrointestinal, and anti-infectives, which constitute around 38 per cent of the pharmaceutical market, showed robust volume growth at 10.6 per cent, 10.1 per cent, and 6.5 per cent, respectively. While top players registered modest monthly value growth in the domestic market during the month, players such as P&G (20.1 per cent), Bayer (15.9 per cent), La Renon (14.6 per cent), Torrent (14.1 per cent), and Sun Pharma (13.7 per cent) posted significant monthly value growth.
Time of India
04-05-2025
- Health
- Time of India
Antacid sales in Gujarat surge amid growing self medication concerns
SLUG: GUT CHECK Ahmedabad: The sale of antacids in Gujarat surged 73% over five years, prompting concern among health professionals about widespread self-medication and overuse of these commonly available stomach-settling drugs. Data from health-tech platform Pharmarack shows that the state's antacid market grew from Rs 230 crore in 2020 to Rs 398 crore in 2025. This was just the tip of the iceberg. The broader gastrointestinal (GI) segment — covering acidity, indigestion, nausea, diarrhoea, and more — ballooned from Rs 603 crore to Rs 1,062 crore, a 76% jump during the same period. Antacids alone now account for 38% of Gujarat's GI drug market. The past year alone saw a sharp 21% spike in antacid sales — up from Rs 329 crore in FY24. According to Sheetal Sapale, vice president (commercial) at Pharmarack, this growth was particularly notable in FY25, partly due to the frequent temperature fluctuations and increased viral infections. "With the temperature changes, viral infections caught up, and body pain, commonly associated with these infections, led to a spike in the use of painkillers, which in turn induce acidity. Additionally, infections cause weakness, leading to greater consumption of ORS and probiotics," she explained. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AI guru Andrew Ng recommends: Read These 5 Books And Turn Your Life Around in 2025 Blinkist: Andrew Ng's Reading List Undo Doctors attribute the trend to post-Covid fallout, erratic eating habits, prolonged screen time, lack of physical activity, and a rising reliance on quick fixes. Notably, antacids are now routinely prescribed alongside painkillers and anti-infective medications to mitigate gastric side effects. Dr Sanjay Rajput, a city-based gastroenterologist, said rampant use of steroids, antibiotics, and painkillers during the Covid pandemic triggered widespread gastritis. "Yes, doctors have been prescribing more antacids, but there's also a parallel surge in self-medication. Many branded antacids are bought over the counter without any consultation. Plus, antacids are often paired with other drugs to reduce gastric side effects — so this growth reflects a broader spike in overall medication," he said. Pharma distributors confirm that the demand for antacids hasn't slowed since the pandemic. The trend is especially strong among younger consumers, driven by poor diets, stress, and irregular routines, and all the more so as a function of the ease of ordering food. "People think antacids are harmless because they're prescribed so often. Worse, many youngsters complain lately of acidity and flatulence more often than normal, many of whom are administered antacids by their parents without consulting the doctor. We estimate 25–30% of sales now come from self-medication. Antibiotics are now tightly regulated, but antacids remain a free-for-all," said Jashvant Patel, president of the Federation of Gujarat State Chemists and Druggists' Association.
